MYC and cancer: Pancancer analysis across the 33 cancers of The Cancer Genome Atlas (TCGA) identified focal amplification (28% of the samples) in at least one of the three MYC families, and MYC antagonists were mutated (MGA, 4% of samples) or deleted (MNT, 10% of samples) [79].